Compare Amplify Cybersecurity ETF (HACK) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Cybersecurity ETF vs Novo Nordisk A/S — how do they compare? Amplify Cybersecurity ETF trades at $130.76 (market cap $3.50B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 47.2× Amplify Cybersecurity ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Amplify Cybersecurity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Amplify Cybersecurity ETF for 28 Days and Novo Nordisk A/S for 116 Days on average.
| HACK | NVO | |
|---|---|---|
Market Cap | $3.50B | $165.31B |
Volume | 341,176 | 11,432,838 |
Sector | Sector/Thematic | Health |
52-Week High | $130.76 | $63.98 |
52-Week Low | $70.69 | $35.29 |
Typical Hold Time | 28 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HACK trades at $130.76, up 3.93% today and near its 52-week high, reflecting strong momentum amid bullish technical signals. The ETF benefits from rising cybersecurity demand driven by AI safety concerns and recent earnings beats from holdings like CrowdStrike. Technical indicators show a bullish trend with support at $124 and resistance at $126, while short interest has surged, indicating mixed sentiment.
Outlook remains positive due to sector tailwinds from AI-driven cyber threats, but risks include high valuation sensitivity and increased short interest. The ETF's diversified exposure to cybersecurity leaders offers growth potential, though investor caution is warranted given its proximity to record highs and competitive pressures.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amplify Cybersecurity ETF
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
